HomeCare Guidelines

Care Guidelines

Duchenne Muscular Dystrophy Speech Delay: Understanding Language Development in Children with DMD

Duchenne muscular dystrophy speech delay is an important developmental concern that families and healthcare professionals should recognize. Although Duchenne muscular dystrophy (DMD) is primarily known as a genetic neuromuscular condition causing progressive muscle weakness, research has shown that some boys with DMD can also experience differences or delays in...

Guide to DMD for Parents and Teachers at School: A Complete Guide for Safety, Learning, Friendship and Inclusion

A well-structured guide to DMD for parents and teachers at school is essential for supporting children with Duchenne Muscular Dystrophy (DMD) in educational environments. DMD is a progressive neuromuscular condition that affects muscle strength, endurance, and sometimes cognitive functioning. These challenges directly influence how a child participates in school...
spot_img

Keep exploring

Better Night’s Sleep with BiPAP Machine: A Complete Guide for DMD Patients and Caregivers

Living with Duchenne muscular dystrophy (DMD) comes with many daily challenges, and breathing difficulties...

Multidisciplinary Neuromuscular Team in Duchenne Muscular Dystrophy (DMD): Roles and Benefits

Duchenne muscular dystrophy (DMD) is a progressive, genetic neuromuscular disorder that affects muscle strength,...

What Are the Pros and Cons of Steroids (Cortisone) for Duchenne Muscular Dystrophy (DMD)?

Duchenne Muscular Dystrophy (DMD) is a progressive genetic disorder that causes muscle weakness and...

When Is The Best Time for a Power Wheelchair in DMD?

For families navigating a diagnosis of Duchenne muscular dystrophy (DMD), mobility changes are a...

How Does Duchenne Affect Dental Health? A Comprehensive Guide for Parents and Caregivers

Duchenne muscular dystrophy (DMD) is a progressive genetic disorder that primarily affects muscle strength...

What is Rhabdomyolysis in Duchenne Muscular Dystrophy: Symptoms, Causes, Treatment

Rhabdomyolysis is a serious medical condition involving the rapid breakdown of muscle tissue, leading...

Ankle Foot Orthosis (AFO) in Duchenne Muscular Dystrophy (DMD): Benefits, Uses, and Care Tips

Ankle Foot Orthosis (AFO) devices are pivotal in assisting individuals with Duchenne Muscular Dystrophy...

What Duchenne Muscular Dystrophy (DMD) Patients Who Need to Have Surgery Under Anesthesia Should Know

While medical advancements have significantly improved the quality of life for DMD patients, surgical...

Glucocorticoid Use in DMD Patients and Impact on Growth Effect

A childhood hereditary disorder known as Duchenne muscular dystrophy (DMD) is characterized by increasing...

Latest articles

Entrada Therapeutics ENTR-601-45: Early Exon 45 Skipping Study Shows Increased Dystrophin Production

Entrada Therapeutics has announced positive initial results from its Exon 45 Skipping Study, ELEVATE-45-201,...

Entrada Therapeutics Advances ENTR-601-44 to 18 mg/kg in Its Duchenne Exon 44 Skipping Study

Entrada Therapeutics has received clearance to test the highest dose in its Exon 44...

Sapreme Therapeutics Reports Strong Preclinical Dystrophin Restoration With SPM-2551 in Duchenne

Sapreme Therapeutics has announced promising preclinical results for SPM-2551, an experimental treatment for Duchenne...

Deramiocel Shows Positive 24-Month HOPE-3 Results in Duchenne

Capricor Therapeutics has reported new results from the HOPE-3 study evaluating Deramiocel in people...

Ractigen Therapeutics Reports Positive First-in-Human Data for RAG-18 in Duchenne

Ractigen Therapeutics has presented positive first-in-human data for RAG-18 (NCT07282652), an investigational treatment for...

Entrada Therapeutics’ ENTR-601-44 Shows Dose-Dependent Exon 44 Skipping in Early PK/PD Data

Entrada Therapeutics’ ENTR-601-44 is an investigational therapy designed for patients with Duchenne muscular dystrophy...

NS Pharma’s Brogidirsen Shows 5-Year Clinical Data in DMD Patients Amenable to Exon 44 Skipping

NS Pharma’s brogidirsen (NS-089/NCNP-02) is an investigational therapy for Duchenne muscular dystrophy (DMD) designed...

ELEVIDYS WMS 2026 Data: What They Show—and What They Don’t

Sarepta Therapeutics has presented new data on ELEVIDYS (delandistrogene moxeparvovec) at the 2026 World...